4 Days
Source:
الصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
4 Daysالصحة والعلوم الشرق الأوسط
Source: الصحة والعلوم الشرق الأوسط
4 DaysReady to play
Ready to play
The U.S. Food and Drug Administration has tentatively approved a generic version of lenacapavir, a twice-yearly injection to prevent HIV, potentially speeding its availability in 120 low- and middle-income countries. It is expected to cost about $40 per person per year, while efforts to expand access to the drug aim to reach around 20 million people who need pre-exposure prevention. The generic version cannot currently be sold in the United States because the original drug is protected by a patent. Use of lenacapavir also requires an HIV test before treatment and with each dose.
Notice: This Is an AI-Generated Summary
Comments (0)